deltatrials

Triple negative breast neoplasms Trials in Chicago, United States

Conditions / Triple negative breast neoplasms / Chicago, United States

Clinical trials for Triple negative breast neoplasms investigate a range of treatment strategies and patient populations.

11 total trials for this combination

Showing top 10 of 11 trials

Trials

NCT ID Title Status Phase
NCT01969643 A Safety Study of SGN-LIV1A in Breast Cancer Patients COMPLETED PHASE1
NCT03225547 Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer TERMINATED PHASE2
NCT06841354 A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) RECRUITING PHASE3
NCT03997123 Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC ACTIVE_NOT_RECRUITING PHASE3
NCT04879849 A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers COMPLETED PHASE1
NCT04191135 Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) COMPLETED PHASE2
NCT03036488 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) COMPLETED PHASE3
NCT05194072 A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors TERMINATED PHASE1
NCT02299635 A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations TERMINATED PHASE2
NCT02720185 Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR TERMINATED PHASE2

Related Pages